arrow
E

Eduardo García-Galea

vall dhebron institute of oncology
H指数:7
被引数:215

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

帕利妥单抗德鲁克特肯长期疗效的决定因素:基于乳腺癌患者来源异种移植模型

2025-11-210
OAAI
Young-Onset Biliary Tract Cancers: Characteristics, Treatment Patterns, and Patient Outcomes

早发型胆道系统癌症:特征、治疗模式及患者预后

2025-08-110
OAAI
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial

一项Ib/II期临床试验,将brentuximab vedotin与环磷酰胺、丙卡巴肼、泼尼松、依托泊苷和米托蒽醌(BrEPEM)联合用于未经治疗的老年经典型霍奇金淋巴瘤患者:一项多中心GELTAMO试验

2025-07-250
PRE
Real-world data of patients (pts) with BRAF V600E-mutated (mt) metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTDeTPI)

用三氟尿苷/替吡嘧啶 (FTDeTPI) 治疗的BRAF V600E-mutated (mt) 转移性结直肠癌 (mCRC) 患者 (pts) 的真实世界数据

2024-06-010
PRE
Association of clinicopathological (C-P) features and tumor (tum) immune contexture with dissemination pattern in metastatic colorectal cancer (mCRC)

转移性结直肠癌 (mCRC) 的临床病理 (c-p) 特征和肿瘤 (tum) 免疫环境与扩散模式的关联

2024-06-010
PRE
Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
2023-10-010
PRE